Defender Capital LLC. Buys Shares of 6,829,099 Lineage Cell Therapeutics, Inc. $LCTX

Defender Capital LLC. bought a new stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,829,099 shares of the company’s stock, valued at approximately $11,405,000. Lineage Cell Therapeutics comprises approximately 3.7% of Defender Capital LLC.’s investment portfolio, making the stock its 10th biggest holding. Defender Capital LLC. owned approximately 2.96% of Lineage Cell Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. SG Americas Securities LLC acquired a new position in Lineage Cell Therapeutics during the 4th quarter valued at approximately $25,000. Millennium Management LLC increased its position in Lineage Cell Therapeutics by 3.1% in the third quarter. Millennium Management LLC now owns 2,680,003 shares of the company’s stock worth $4,529,000 after buying an additional 79,426 shares during the period. Bank of America Corp DE increased its position in Lineage Cell Therapeutics by 126.0% in the third quarter. Bank of America Corp DE now owns 233,436 shares of the company’s stock worth $395,000 after buying an additional 130,124 shares during the period. Raymond James Financial Inc. lifted its stake in Lineage Cell Therapeutics by 30.3% in the third quarter. Raymond James Financial Inc. now owns 90,381 shares of the company’s stock valued at $153,000 after buying an additional 21,001 shares during the last quarter. Finally, Equitable Holdings Inc. bought a new stake in Lineage Cell Therapeutics in the third quarter valued at $51,000. 62.47% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently commented on LCTX. D. Boral Capital upped their price target on shares of Lineage Cell Therapeutics from $2.00 to $3.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. B. Riley Financial lifted their price objective on shares of Lineage Cell Therapeutics from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a research note on Tuesday. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $5.33.

Lineage Cell Therapeutics Price Performance

LCTX opened at $1.55 on Thursday. The stock’s 50 day moving average price is $1.69 and its 200 day moving average price is $1.69. The stock has a market cap of $386.09 million, a P/E ratio of -5.54 and a beta of 1.74. Lineage Cell Therapeutics, Inc. has a 12 month low of $0.37 and a 12 month high of $2.09.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.07. Lineage Cell Therapeutics had a negative return on equity of 76.13% and a negative net margin of 436.47%.The company had revenue of $6.61 million during the quarter, compared to analyst estimates of $1.96 million. Equities analysts anticipate that Lineage Cell Therapeutics, Inc. will post -0.12 EPS for the current year.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.